Focal launches FocalSeal through Ethicon:
This article was originally published in Clinica
Focal is to launch its FocalSeal surgical sealant in New Zealand, Australia, Hong Kong and South Africa, through Johnson & Johnson subsidiary Ethicon. Lexington, Massachusetts-based Focal's product will be marketed and distributed under the brandname Advaseal. The product is a synthetic, absorbable liquid sealant which is designed to prevent air leaks during lung surgery. Visible light from a specially-designed light source transforms the liquid into a tissue-adherent gel which creates a leak-proof seal over the wound.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.